Table 3. Nested Case-Control Analyses of Baseline Characteristics in Patients With Deep and Lobar Intracerebral Hemorrhage.
| Characteristic | Deep ICH | Lobar ICH | ||||||
|---|---|---|---|---|---|---|---|---|
| Patient group, No./total No. (%) | Control group, No./total No. (%) | OR (95% CI)a,b | P value | Patient group, No./total No. (%) | Control group, No./total No. (%) | OR (95% CI)a,b | P value | |
| Total No. | 44 | 176 | NA | NA | 55 | 220 | NA | NA |
| Age at matching, mean (SD), y | 78 (12) | 78 (12) | NA | NA | 76 (13) | 76 (12) | NA | NA |
| Male sex | 21/44 (47.7) | 84/176 (47.7) | NA | NA | 24/55 (43.6) | 96/220 (43.6) | NA | NA |
| Educational level | ||||||||
| High school graduate | 31/44 (70.5) | 111/172 (64.5) | 1.32 (0.63-2.76) | .47 | 36/52 (69.2) | 155/212 (73.1) | 0.90 (0.43-1.88) | .79 |
| College graduate | 8/44 (18.2) | 25/172 (14.5) | 1.20 (0.49-2.92) | .70 | 7/52 (13.5) | 43/212 (20.2) | 0.57 (0.24-1.38) | .21 |
| Blood pressure, mean (SD), mm Hgc | ||||||||
| Systolic | 154 (26) | 143 (22) | 1.02 (1.01-1.04) | .008 | 148 (26) | 138 (23) | 1.02 (1.01-1.04) | .002 |
| Diastolic | 81 (17) | 76 (13) | 1.04 (1.01-1.07) | .01 | 77 (14) | 75 (13) | 1.02 (0.99-1.04) | .20 |
| Pulse pressure, mean (SD), mm Hg | 73 (23) | 67 (19) | 1.01 (1.00-1.03) | .18 | 71 (21) | 63 (20) | 1.03 (1.01-1.05) | .002 |
| Hypertension | 37/43 (86.0) | 126/174 (72.4) | 2.65 (0.98-7.16) | .06 | 42/53 (79.2) | 132/216 (61.1) | 2.89 (1.30-6.43) | .009 |
| Cardiovascular disease | 19/44 (43.2) | 52/176 (29.5) | 1.78 (0.87-3.64) | .11 | 18/55 (32.7) | 62/220 (28.2) | 1.13 (0.58-2.18) | .72 |
| Diabetes | 9/35 (25.7) | 17/133 (12.3) | 2.74 (0.98-7.67) | .06 | 4/43 (9.3) | 29/170 (17.1) | 0.40 (0.13-1.28) | .12 |
| Atrial fibrillation | 9/44 (20.5) | 21/176 (11.9) | 2.05 (0.79-5.35) | .14 | 6/55 (10.9) | 14/220 (6.4) | 1.68 (0.60-4.69) | .32 |
| Smoking | 3/41 (7.3) | 18/166 (10.8) | 0.74 (0.20-2.77) | .66 | 8/51 (15.7) | 30/208 (14.4) | 1.09 (0.45-2.63) | .85 |
| Total cholesterol, mean (SD), mg/dLc | 198 (42) | 204 (43) | 1.00 (0.99-1.01) | .75 | 203 (47) | 202 (41) | 1.00 (0.99-1.01) | .95 |
| High-density lipoprotein, mean (SD), mg/dLc | 52 (14) | 20 (14) | 1.00 (0.96-1.05) | .85 | 53 (16) | 55 (17) | 0.98 (0.95-1.02) | .33 |
| Statin usec | 7/21 (33.3) | 12/88 (13.6) | 4.07 (1.16-14.21) | .03 | 5/20 (25.0) | 21/84 (25.0) | 0.99 (0.29-3.38) | .98 |
| Anticoagulant usec | 4/31 (12.9) | 10/136 (7.4) | 2.37 (0.60-9.35) | .22 | 3/33 (9.1) | 4/137 (2.9) | 3.05 (0.66-14.06) | .15 |
| APOE4 c | 6/27 (22.2) | 25/132 (18.9) | 1.15 (0.40-3.29) | .80 | 11/28 (39.3) | 28/143 (19.6) | 3.66 (1.28-10.43) | .02 |
| APOE4 homozygous vs APOE3 homozygous, %c | 6/21 (28.6) | 24/109 (22.0) | 1.19 (0.39-3.64) | .76 | 10/23 (43.5) | 25/123 (20.3) | 5.64 (1.42-22.31) | .01 |
Abbreviations: APOE3, apolipoprotein E ε3 allele; APOE4, apolipoprotein E ε4 allele; ICH, intracerebral hemorrhage, NA, not applicable; OR, odds ratio.
a
OR for patient group.
b
OR was adjusted for age and time between clinical assessment and stroke event or matching date, respectively.
c
Missing data in more than 10% of participants.